Research Plan

2. Specific Aims

Eukaryotic innate immune systems act as effective barriers to infection by microorganisms. Understanding the mechanisms that bacterial pathogens employ to circumvent innate immune systems will improve our ability to control disease. Plants and animals use specific pattern recognition receptors (PRRs) to recognize conserved molecules of microorganisms (known as PAMPs). Plants have numerous PRRs that can recognize specific virulence proteins specifically present in pathogens (known as Avr proteins). Many Gram-negative bacteria use type III protein secretion systems to inject effector proteins into host eukaryotic cells. We have shown that a primary role for many *Pseudomonas syringae* type III effectors is to suppress innate immunity. However, the enzymatic activities and the mechanisms that type III effectors use to suppress innate immunity are not well understood. Identifying the enzymatic activities of type III effectors and their substrates is essential to identify important components of innate immunity and to improve strategies to control bacterial diseases.

Our *long-term goal* is to elucidate the molecular basis for suppression of innate immunity by type III effectors. The objective of this application is to identify targets of the *P. syringae* type III effector HopU1, a mono-ADP-ribosyltransferases (ADP-RTs), and to determine its roles in bacterial pathogenesis. *The central hypothesis of the proposed experiments is that the targets of the HopU1 ADP-RT type III effector will be components of innate immunity.* We formulated this hypothesis based on the literature and on our research on other type III effectors as well as our preliminary data showing that HopU1 suppresses outputs of innate immunity. Recently, we have shown that HopU1 can use several *Arabidopsis* RNA-binding proteins as high affinity substrates in *in vitro* ADP-RT assays. Based on our preliminary data, one of these proteins, *At*GRP7, plays a role in innate immunity. A major goal of this application is to elucidate the function of this protein as it relates to innate immunity. We are prepared to undertake the proposed research because we have extensive experience in manipulating type III systems, and we were among the first to report that certain type III effectors suppress innate immunity. In addition, our preliminary identification of HopU1's substrates has positioned us well to perform the experiments described in this application. Our research team includes experts in the following areas: type III secretion systems, proteomics and mass spectrometry, Affymetrix microarrays, plant glycine-rich RNA-binding proteins, and animal pathogen ADP-RTs. This qualified group of investigators will insure that our discoveries are linked to basic concepts of pathogenesis and immunity in both plants and animals.

The Specific Aims of this application are as follows:

1. **Determine the molecular consequence of ADP-ribosylation on the function of *At*GRP7 and elucidate the role this protein plays in innate immunity.** Our *working hypothesis* of this aim is that *At*GRP7 binds to immunity-related RNAs to enhance the innate immune response and that ADP-ribosylation by HopU1 disrupts its function.

2. **Identify additional substrates of HopU1 and verify their involvement in innate immunity.** Our *working hypothesis* is that the plant targets for the HopU1 ADP-RTs will be important components of plant innate immunity.

3. **Analyze the affect that HopU1 has on host-microbe interactions.** Our *working hypothesis* of this aim is that HopU1 type III effector suppresses innate immunity. This is based on our preliminary data and in this aim we will determine to what extent this occurs with *HopU1*.

The proposed research is innovative because, to date, ADP-RTs have not been implicated in the suppression of innate immune surveillance systems. Moreover, RNA-binding proteins have not been described as substrates for ADP-RTs and, therefore, represent novel substrates for this important group of bacterial toxins. Collectively, we expect the outcomes of these experiments will greatly add to our understanding of the activities and roles of type III effectors, particularly in how they suppress innate immunity in eukaryotes.